FDA 483 - Glenmark Pharmaceuticals Ltd - February 14, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Glenmark Pharmaceuticals Ltd in Pithampur, India, revealed critical deficiencies in contamination control, facility segregation, and quality control. The firm failed to prevent cross-contamination due to inadequate cleaning and shared manufacturing areas for potent drugs. Additionally, there were significant issues with OOS investigations, analytical method validation, and timely completion of stability studies, indicating a systemic breakdown in quality assurance.
ID · 1cc89a1d-cf2b-4d72-9e95-834b6d737023